Evercore ISI Cuts Baxter International (NYSE:BAX) Price Target to $24.00

Baxter International (NYSE:BAX) had its price target lowered by Evercore ISI from $31.00 to $24.00 in a report published on Thursday,MarketScreener reports.

Several other research firms have also commented on BAX. Jefferies Financial Group lowered their price objective on Baxter International from $25.00 to $21.00 and set a “hold” rating on the stock in a research report on Thursday. Stifel Nicolaus restated a “hold” rating and issued a $25.00 price objective (down previously from $36.00) on shares of Baxter International in a research report on Monday, August 4th. UBS Group lowered their price objective on Baxter International from $24.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday. Barclays lowered their price objective on Baxter International from $41.00 to $36.00 and set an “overweight” rating on the stock in a research report on Monday, August 4th. Finally, The Goldman Sachs Group lowered Baxter International from a “buy” rating to a “neutral” rating and set a $25.00 price objective on the stock. in a research report on Friday, August 1st. Two investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Baxter International currently has a consensus rating of “Hold” and an average price target of $23.70.

Baxter International Trading Down 3.6%

Baxter International stock opened at $18.47 on Thursday. The company has a current ratio of 2.30, a quick ratio of 1.49 and a debt-to-equity ratio of 1.30. Baxter International has a 12 month low of $18.42 and a 12 month high of $37.74. The stock’s 50 day simple moving average is $23.14 and its two-hundred day simple moving average is $26.85. The firm has a market cap of $9.48 billion, a PE ratio of -61.55, a P/E/G ratio of 0.73 and a beta of 0.58.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, October 30th. The medical instruments supplier reported $0.69 EPS for the quarter, topping the consensus estimate of $0.60 by $0.09. Baxter International had a positive return on equity of 16.96% and a negative net margin of 1.42%.The business had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.88 billion. During the same quarter in the prior year, the firm posted $0.80 EPS. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS. FY 2025 guidance at 2.350-2.400 EPS. Analysts anticipate that Baxter International will post 2.48 earnings per share for the current year.

Institutional Investors Weigh In On Baxter International

A number of institutional investors have recently added to or reduced their stakes in BAX. Zions Bancorporation National Association UT acquired a new stake in Baxter International in the 1st quarter valued at $27,000. CoreFirst Bank & Trust acquired a new stake in Baxter International in the 2nd quarter valued at $27,000. Rossby Financial LCC purchased a new position in Baxter International in the 1st quarter valued at $29,000. Creative Financial Designs Inc. ADV lifted its holdings in Baxter International by 169.6% in the 2nd quarter. Creative Financial Designs Inc. ADV now owns 984 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 619 shares in the last quarter. Finally, MTM Investment Management LLC purchased a new position in Baxter International in the 2nd quarter valued at $30,000. Institutional investors and hedge funds own 90.19% of the company’s stock.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.